Pre-Transplant Donor-Specific T-Cell Alloreactivity Is Strongly Associated with Early Acute Cellular Rejection in Kidney Transplant Recipients Not Receiving T-Cell Depleting Induction Therapy
Fig 5
T-cell depletion induction therapy provides protection against early TCMR.
5a. Patients receiving T-cell depletion as induction therapy showed significantly lower incidence of early TCMR [3.8% (1/26) vs 22% (14/64) p = 0.038] than those that did not.5b. Incidence of early TCMR in anti-donor T-cell sensitized patients receiving either anti-IL2 receptor blockade or rATG. A higher incidence of early TCMR was observed among highly T-cell sensitized patients receiving anti-IL2 receptor blockade than in patients receiving rATG [36.4% (8/22) and 8% (1/12); p = 0.07 respectively].